Earnings Results

Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker

Last Updated: Feb. 6, 2025 at 10:36 a.m. ET
First Published: Feb. 6, 2025 at 7:05 a.m. ET

Eli Lilly said its Zepbound and Mounjaro drugs drove a 45% revenue boost in the fourth quarter. Photo: Scott Olson/Getty Images

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

The drugmaker’s stock LLY rose 0.5% in regular trading on Thursday after the company said it expects to generate an adjusted 2025 profit of $22.50 a share to $24 a share in 2025, compared with the FactSet consensus estimate of $22.76 a share for 2025.